CDT — CDT Equity Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1896212 ·
Last close
$0.88
Market Cap
$4.30M
52W High
$18.25
52W Low
$0.79
ADV30
140,893
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -21,156,000 | -21,325,000 | 5,650,000 | 1,509,000 | 12,820,000 |
| Sep 2025 | 0 | — | -6,936,000 | -7,118,000 | 8,552,000 | 3,838,000 | 4,274,000 |
| Jun 2025 | 0 | — | -4,952,000 | -6,028,000 | 7,989,000 | 3,332,000 | 4,460,000 |
| Mar 2025 | 0 | — | -3,616,000 | -4,753,000 | 7,321,000 | 2,130,000 | 4,634,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,555,000
Investing CF
$-808,000
Financing CF
$17,422,000
CapEx
$-2,403,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-25271.62
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-68,325,000
Inventory
—
Receivables
$398,000
ST Investments
$81,000
EBIT TTM
$-38,905,000
Pretax Income TTM
$-39,224,000
Interest Exp TTM
$319,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -36,660,000 | -39,224,000 | 5,650,000 | 12,820,000 | — | -15,555,000 |
| Dec 2024 | 0 | -15,105,000 | -17,802,000 | 4,193,000 | 10,986,000 | — | -9,682,000 |
| Dec 2023 | 0 | -5,262,000 | -535,000 | 7,224,000 | 7,681,000 | — | -7,725,000 |
| Dec 2022 | 0 | -3,160,000 | -4,887,000 | 5,000 | 10,094,000 | — | -2,266,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACUT | Accustem Sciences Inc. | $4.34M | $0.27 | — |
| ALZN | Alzamend Neuro, Inc. | $4.38M | $1.15 | — |
| MBIO | MUSTANG BIO, INC. | $4.19M | $0.62 | — |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.16M | $0.63 | — |
| REVB | REVELATION BIOSCIENCES, INC. | $4.14M | $1.06 | — |
News headlines (Yahoo Finance, 1h cache)
CDT Equity Advances AstraZeneca PLC (AZN)’s AZD5904 Into PCT Patent Protection Stage
2026-05-11 20:01 · Yahoo
CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
2026-05-07 12:30 · Yahoo
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
2026-05-06 12:30 · Yahoo
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
2026-04-16 12:30 · Yahoo
CDT Notes Sarborg Publication of PRISM Framework Expanding AI
2026-04-07 12:30 · Yahoo
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
2026-03-26 12:30 · Yahoo
CDT Equity Inc. Announces Reverse Stock Split
2026-03-25 12:00 · Yahoo
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
2026-03-23 12:30 · Yahoo
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth
2026-03-18 12:30 · Yahoo
CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence
2026-03-12 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.